The PD-L1 antibodies, atezolizumab, durvalumab, and avelumab, also showed promising response rates as immunotherapy in NSCLC even with low PD-L1 TPS [6, 30]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.